Stock 4168 GLYCONEX INCORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials GlycoNex Incorporation

Equities

4168

TW0004168000

Biotechnology & Medical Research

End-of-day quote Taipei Exchange
Other stock markets
 06:00:00 2024-05-06 pm EDT 		5-day change 1st Jan Change
24.9 TWD 0.00% Intraday chart for GlycoNex Incorporation -2.35% -16.30%
Mar. 19 GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,750 1,546 2,798 2,885 3,261 3,219
Enterprise Value (EV) 1 1,402 1,365 2,320 2,554 2,806 2,519
P/E ratio -5.52 x -6.24 x -15.7 x -16.6 x -13.8 x -18 x
Yield - - - - - -
Capitalization / Revenue 1,889 x 2,106 x 6,205 x 527 x 108 x 1,266 x
EV / Revenue 1,514 x 1,860 x 5,143 x 466 x 93.3 x 991 x
EV / EBITDA -5.28 x -6.33 x -13.8 x -15.5 x -14.1 x -11 x
EV / FCF -10.4 x -13.2 x -26 x -26.4 x -25.2 x 28 x
FCF Yield -9.65% -7.57% -3.84% -3.78% -3.97% 3.57%
Price to Book 1.14 x 1.19 x 1.81 x 2.12 x 2.26 x 2.53 x
Nbr of stocks (in thousands) 75,739 75,957 97,508 97,482 107,098 108,208
Reference price 2 23.10 20.35 28.70 29.60 30.45 29.75
Announcement Date 3/28/19 3/30/20 3/24/21 3/28/22 3/31/23 3/19/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 0.926 0.734 0.451 5.475 30.08 2.542
EBITDA 1 -265.8 -215.8 -167.5 -164.9 -199 -228.7
EBIT 1 -321.6 -269.9 -214.1 -194.9 -238.9 -259.9
Operating Margin -34,727.97% -36,766.08% -47,476.5% -3,560.33% -794.24% -10,222.82%
Earnings before Tax (EBT) 1 -317.6 -246.7 -161.4 -172.5 -219.8 -163.7
Net income 1 -316.9 -247.2 -162.7 -172.5 -219.8 -178.4
Net margin -34,227.11% -33,682.15% -36,082.26% -3,150.56% -730.67% -7,016.6%
EPS 2 -4.185 -3.260 -1.832 -1.780 -2.210 -1.654
Free Cash Flow 1 -135.4 -103.3 -89.06 -96.62 -111.4 89.98
FCF margin -14,617.31% -14,077.86% -19,747.37% -1,764.8% -370.4% 3,539.57%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/28/19 3/30/20 3/24/21 3/28/22 3/31/23 3/19/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 347 180 479 332 455 700
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -135 -103 -89.1 -96.6 -111 90
ROE (net income / shareholders' equity) -18.8% -17.5% -11.5% -11.9% -15.7% -13.1%
ROA (Net income/ Total Assets) -11.7% -11.7% -9.21% -8.21% -9.6% -9.93%
Assets 1 2,703 2,121 1,767 2,102 2,290 1,795
Book Value Per Share 2 20.20 17.10 15.90 13.90 13.50 11.70
Cash Flow per Share 2 3.380 1.560 1.570 1.280 0.7700 1.380
Capex 1 3.22 1.5 1.87 6.84 8.69 23.4
Capex / Sales 347.73% 203.81% 415.08% 124.91% 28.88% 921.32%
Announcement Date 3/28/19 3/30/20 3/24/21 3/28/22 3/31/23 3/19/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GLYCONEX INCORPORATION Stock GlycoNex Incorporation
-16.30% 83.68M
MODERNA, INC. Stock Moderna, Inc.
+20.03% 46.81B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.08% 41.37B
LONZA GROUP AG Stock Lonza Group AG
+47.07% 41.29B
CELLTRION, INC. Stock Celltrion, Inc.
-3.52% 28.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+11.64% 26.06B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.55% 19.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.60% 12.39B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.02% 12.08B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.27% 11.96B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 4168 Stock
  4. Financials GlycoNex Incorporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW